Table 1.
Study Cohort Demographics, Comorbidities, and Treatments
| Characteristic | MIS-C | SAC | CFR |
|---|---|---|---|
| (n = 19) | (n = 18) | (n = 7) | |
| Demographic characteristics | |||
| Age, y, average (min–max) | 9.24 (0.27–17.6) | 10.14 (0.03–20.4) | 11.0 (5.30–18.0) |
| Female sex, % | 47 | 55 | 57 |
| Race, No. | |||
| Asian | 1 | 1 | 0 |
| Black | 5 | 6 | 4 |
| White | 3 | 4 | 2 |
| Native American/Alaska Native | 0 | 0 | 1 |
| Other | 10 | 7 | 0 |
| Ethnicity, No. | |||
| Hispanic | 11 | 9 | 0 |
| Non-Hispanic | 8 | 9 | 7 |
| Comorbidities | |||
| Average BMI, kg/m2 | 23.65 | 25.38 | 18.73 |
| Average BMI percentile | 87.02 | 79.66 | 60.00 |
| Chronic condition, No. (%)a | 5 (26) | 13 (72) | 0 (0) |
| Immunocompromising condition, No. (%) | 0 (0) | 3 (17) | 0 (0) |
| ICU characteristics | |||
| ICU hospitalization, No. (%)b | 15 (79) | 7 (39) | NA |
| Supplemental oxygen, No. | 8 | 7 | NA |
| Pressors, No. | 8 | 0 | NA |
| Treatment characteristics, No.c | |||
| IVIG | 14 | 1 | NA |
| Steroids | 6 | 1 | NA |
| Remdesivir | 2 | 1 | NA |
| Convalescent plasma | 0 | 2 | NA |
Abbreviations: BMI, body mass index; CFR, children fully recovered from coronavirus disease 2019; ICU, intensive care unit; IVIG, intravenous immunoglobulin; MIS-C, multisystem inflammatory syndrome in children; NA, not applicable; SAC, severe acute coronavirus disease 2019.
aChronic conditions include the following: participants with MIS-C: asthma (n = 3), chromosomal/genetic syndromes (n = 2), developmental delays (n = 2), chronic lung disease (n = 1). Participants with SAC: asthma (n = 3), chromosomal/genetic syndromes (n = 2), sickle cell disease (n = 1), chronic pulmonary disease (n = 1), type 2 diabetes mellitus (n = 1), prematurity (n = 1), seizures (n = 1).
bImmunocompromised conditions include the following: Participants with SAC: myelodysplastic syndrome (n = 1), hematopoietic stem cell transplantation (n = 1), liver transplant recipient (n = 1).
cPatients may have received >1 treatment.